Pharmacyclics — Technical Presentation (September 2013)
26 slides from Pharmacyclics's technical presentation, Sep 10, 2013
Slide 1: Ibrutinib Promotes a High Frequency of Durable Response in CLL: Final Results of Phase Ib/II Study
The Bruton Tyrosine Kinase (BTK) Inhibitor Ibrutinib Promotes a High Frequency of Durable Response in Relapsed/ Refractory and Older Treatment-Naive CLL Patients: Final Results of a Phase Ib/II Study Richard R. Furman, MD!, Susan O'Brien, MD2, lan W. Flinn, MD, PhD?, Jan Burger, MD, PhD?, Kristie Bl
Slide 2: Disclosure: Dr. Furman has served on Pharmacyclics advisory boards
® Dr. Richard Furman has served on advisory boards sponsored by Pharmacyclics, Inc. {CLL 2013, PCYC 1102, Furman et a. 2
Slide 3: Bruton's Tyrosine Kinase (BTK)
Bruton’s Tyrosine Kinase (BTK) ™ BTK is an essential mediator of B-cell receptor signaling in normal and malignant B cells ‘Chemokine-controlied cell migration Honigberget al. Proc Not! Acod Se $4, 2010;107:13075-13060;Ponader etal Blood. 2012;119:1182-1159. {CLL 2013, PCVC 1102, Furman et a. 3
Slide 4: Ibrutinib, an oral inhibitor of BTK, promotes apoptosis and inhibits proliferation
® Ibrutinib(PCI-32765), an oral inhibitor of BTK, promotes apoptosis and inhibits proliferation, migration, and adhesion in CLL cells * Chemoimmunotherapy (CIT) treatments such as fludarabine, cyclophosphamide, and rituximab have markedly improved outcomes in younger, fit patients as initial or seco
Slide 5: Study Design
PCYC 1102 Study Design Phase Ib/II CLL/SLL PCYC - 1102- CA 116 patients treated with ibrutinib monotherapy LL 2013, PCYC 1102, Furman et al. Enrolled May 2010 July 2011 Treatment Naive (TN) 2 65 yrs Relapsed/Refractory (R/R)° 420 mg/d (n=51) n=8 840 mg/d (n=34) Median follow-up 22.1 months *R/Rinclu
Slide 6: Baseline Demographics and Disease Characteristics
PCYC 1102 Baseline Demographics and Disease Characteristics TN2 65 Ye Characteristic steers n=31 Median age, years (range) 71 (65, 84) 66 (37, 82) 270 years, n (%) 23 (74) 30(35) Male, n (%) 19(61) 65 (76) Female, n(%) 12 (39) 20(24) ECOG status, n (%) 0-1 31(100) 83 (98) 2 0 2(2) Median ALC, 10°/L
Slide 7: Baseline Demographics and Disease Characteristics
PCYC 1102 Baseline Demographics and Disease Characteristics ior Treatments 5 Prior therapies, n(%) Median (range) 4(1, 12) <3 24 (28) 23 61 (72) Type of prior therapy, n(%) Nucleoside analog 81(95) Alkylator 76 (89) Rituximab 83 (98) Alemtuzumab 18(21) Bendamustine 33 (39) Ofatumumab 22.(26) Allogen
Slide 8: PCYC 1102 Patient Disposition
| WCLL 2013, PCVC 1102, Furman e al PCYC 1102 Patient Disposition Median time ontreatment, months (range) Median time on study, months (range) Patients still on treatment, n(%) Patients discontinuing treatment, n (%) Primary reasons for treatment discontinuation, n (2%) ABP Treatment-related AE Deat
Slide 9: Safety: Clinically Significant Adverse Events
PCYC 1102 Safety: Clinically Significant Adverse Events 2 Adverse Event, n (%) WES BR 1 85 Any AE grade 23 15 (48) 63 (74) Any ibrutinib-related AE grade 23 5 (16) 24(28) Serious AEs Any 9(29) 52(61) Ibrutinib-related 3(10) 9(11) AEs leading to ibrutinib dose reduction 1(3) 10(12) Deaths within 30 d
Slide 10: Adverse Events of All Grades and Attribution in >15% of Patients
PCYC 1102 Adverse Events of All Grades and Attribution in > 15% of Patients (n=31) (n=85) ihe Daren Lie ‘URTI aie fatigue Hypertension Coumh Asher dea Pia Danes Arabs Dyspepsia. Periheral Edema Ua Hypertension Antal Cnstpaton Constipation Caton ‘Uinry tractinfcton uyclespasns Veoiting Shustis Adon p
Slide 11: Frequency of Grade Adverse Events
PCYC 1102 Frequency of Grade 2 3 Adverse Events Non-hematologic: 5% Hematologic 1 1N Ro: IN me at 50% 40% ' 30% i ae i 0% : 0% A 5 23 $e gee 22 E eEgsaes Bae BEE eg’ oss 33°C iui ou = § 5 Fe oF {WYCLL013,PC¥C 1102, Furman eta. Wicrade3 Mraded Micrades wR fection infe ° 3 3 ‘| 6 é. ea Infectious im 2
Slide 12: Best Overall Response
PCYC 1102 Best Overall Response ORR = (CR+PR) ‘ORR= (CR+ PR) 80% 75% a+ 2% Ma La PRwith Lymphoeytoss Hs 60% 40% 20% 0% N RR (n=31) (n=85) 2not evaluable 4not evaluable IWWCLL2O13, PCYC L102, Furman etal Among those patients whose initial response was PR-L, the majority achieved classic response by i
Slide 13: Best Overall Response by Risk Features
PCYC 1102 Best Overall Response by Risk Features Fy . & Se 8 —- s ~~ B od ” ~_ ” ae 6 ~ 2 —_ » — ECOGat baseline: 0 Bm —— 0 B M3 ~~ m1 8 50 ——| tw me > Raistageat baseline: sugeost 3 e92 == Sugeosl 28 750 ae Stage 7 706 SS StagelleV $2 750 a Bulky disease at baseline: «sem 20 —— sam ah _ Sem 6 67 |
Slide 14: Absolute Lymphocyte Count and Lymph Node Size
PCYC 1102 Absolute Lymphocyte Count and Lymph Node Size TN RR Absolute Lymphocyte Count and Lymph Node Size + 1) 0 1) AC ae “sft 2” on en Fn g 2 mg 0 eo He j 5 £9 KW) ey jos 3 H a 3a 4 Q § aah a Di 33 32 H fa LLD sy ac 0 0 OLIIFSOTEIMTLEMEKTBMAIABY Cyd (8a) Error bars are 95% distribution-free confi
Slide 15: Lymphocytosis
PCYC 1102 Lymphocytosis x 10°/L, n (%) Peak’<50 Total (N= 116) 53 (46) Baseline ALC,n(%) <50(n=86) 53 (62) 50-100 (n= 14) 0 100-300 (n= 16) 0 20fallpatientstreated, 5% (TNJand 78% (R/A} had lyn peak vaximum post-baseline value IWWCLL2O13, PCYCL102, Furman et al Peak 50-100 | Peak 100-400 Peak 2 400
Slide 16: Platelet Counts and Hemoglobin Levels
PCYC 1102 Platelet Counts and Hemoglobin Levels TN RR Platelet Counts and Hemoglobin Levels > ¥ d we 2m o Bou $ ue* H ae E oe eu : ay § iT i2y i -=-fatdels —Henaghtin «= Patdels: Henan OTT IAS STOP MTL OME WTB RMALGM OL ITAS OTOP OTRUMSRTEMMADY Cycle (28 ds) Gide 28 das) Error barsare 95% distributi
Slide 17: Change in Median Serum Immunoglobulin Levels
PCYC 1102 Change in Median Serum Immunoglobulin Levels Serum IgA Serum IgM Serum IgG HE WNor=16) BE RR(n=20) HE Wot3) MRR (n=15) HH Wrt5) MB RR (1-20) 1 Months Error bars are 95% distributic or change from baseline WCLL2013, PCC 1102, Furman et al 7
Slide 18: Progression-Free Survival
PCYC 1102 Progression-Free Survival All Treated Population Del 17p/del 1iq Status (R/R) == 10 Mety., 08 Theis > 08 Z “tena | 2 5 wal B06 B06 fe) ° | — at Ps 226 mois 96.3% | tesep orate ts at mesa 20a) SMe siraaama nes 044 —tuingnrnadtonusis a * 17pdel/11qdel: 02. 02 —— No Wp delortiq del a —iqdel 0
Slide 19: Overall Survival
PCYC 1102 Overall Survival All Treated Population Del 17p/del 1iq Status (F/R) 10 wT 0.8 0.8 _ g 2 4 4 B06 B06 & INE 052 2605 96.6% & tecap ota hse Boa ~~ AIRES. 05226 mols 7.5% B 04 Taattptn aba mnssh6 17pdel/1 1qdel: 02 a 02 No W7p del or Niq del aR —Tigdel 0,0 L+Censored 0.0 1+ Censored =Thdd 0 6
Slide 20: Conclusions
PCYC 1102 Conclusions © |brutinib monotherapy is highly active, well tolerated, and induces durable* responses in patients with CLL — includesR/R patients, those with high-risk disease, and older TN patients ® Randomized trials comparing the safety profile of ibrutinib with those of other therapeuti
Slide 21: Acknowledgements
Acknowledgements Allthe patients who participated in the study and their supportive families Investigators and clinical research staff from all the clinical centers Pharmacyclics, Inc. Sheila Lagura Raquel zum Robert Duggan Stephan Chan Mai Cheng Raquel Garlick Tosh Kameda Cathy Zhou Thorsten Graef
Slide 22: {¥CLL2013, PCYC 1102 .
{¥CLL2013, PCYC 1102 Furman et al. 2
Slide 23: Safety: Treatment-Related Hematologic Adverse Events
PCYC 1102 Safety: Treatment-Related Hematologic Adverse Events Adverse Event, n (%) WES o Hematologic AEs? Anemia 1(3) 6(7) 7(6) Neutropenia 1(3) 9(11) 10(9) Thrombocytopenia 2(6) 7(8) 9(8) ‘Treatment-related AEs occurring in 25% of all patients, IWWCLL2O13, PCYCL102, Furman et al B
Slide 24: Safety: Treatment-Related Nonhematologic Adverse Events
PCYC 1102 Safety: Treatment-Related Nonhematologic Adverse Events 7 TN2 65 Years Adverse Event, n (%) neat Nonhematologic AEs* Diarrhea 12(39) 32(38) 44(38) Fatigue 5 (16) 13(15) 18(16) Arthralgia 3(10) 10(12) 13(11) Contusion 2(6) 11(13) 13(11) Nausea 5 (16) 7(8) 12(10) Dyspepsia 5(16) 5(6) 10(9) M
Slide 25: Hemoglobin Levels
PCYC 1102 Hemoglobin Levels TN R/R Hemoglobin Levels Bi 5 $ 3 3H 3 A i by bal ian j : r ‘i Itt my AL 1 so TNTota i — RRTotl OLIIFSSTIIMTNGKEKTBRMADAM OLAS HTRINMLBHEKTBHHALI tests Cretan) ‘bjfesks ‘ee dap) Wed DBBBITTITIAB SARUM BSE Error bars are 95% distribution-free confidence limits of median {C
Slide 26: Platelet Counts
PCYC 1102 Platelet Counts RR Median Platelets w/ 95% Cle (1079/1) Sssssesee ee INTotal RR Toad OTTIAS OT OU MNREM HOU ORNADAN OTITIS CTE ORRGW ERT ERMA DAR ita) Ode adap) alent nents WedIHBUBIDTVINSY BAND BS MMSOUBHNHHOHHHH @ SO ¥ DR Error barsare 95% distribution-tree confidencelimits of median {CL
Pharmacyclics — Technical Presentation (September 2013) on 6ix